Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 20, 2025, reports on events occurring on August 19, 2025. Vivos Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this report to announce its financial results for the second quarter ended June 30, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report serves as a notification that these results were announced via a press release (Exhibit 99.1) but does not contain the detailed financial data within the body of the 8-K itself.
Material Changes
No material changes versus the prior comparable period are detailed in this filing text. The document references the Q2 2025 results but does not explicitly state year-over-year or quarter-over-quarter variances.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It notes that the information, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 19, 2025) for actual Q2 2025 financial figures.
- Verify the company's cash runway and burn rate, as these are not listed in the 8-K summary.
- Check for any forward-looking statements or updated clinical trial timelines in the referenced press release.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.